Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer
An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer
This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer.
Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety.
A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Yongsheng Jia
- 電話番号:+86-18622199359
- メール:yongshengjia@tjmuch.com
研究場所
-
-
-
Tianjin、中国、300060
- 募集
- Tianjin Medical University Cancer Institute and Hospital
-
コンタクト:
- Yongsheng Jia
- 電話番号:+86-18622199359
- メール:yongshengjia@tjmuch.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged ≥18 and ≤70 years old.
- Histopathologically confirmed invasive breast cancer; no prior systemic anti-tumor therapy for breast cancer.
- Histopathologically confirmed HR-positive (ER >1%) and HER2-low breast cancer. HER2-low is defined as IHC 1+ or IHC 2+ with ISH-negative.
- Ki-67 proliferation index ≥30%.
- Stage II-III breast cancer per the 8th edition AJCC TNM staging criteria (cT2 N1-2 M0, or T3-4 N0-2 cM0).
- At least one measurable target lesion according to RECIST Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Female participants may be pre-menopausal, peri-menopausal or post-menopausal. Post-menopause is defined according to CSCO Breast Cancer Guidelines as any one of the following:
Bilateral oophorectomy;
- Age ≥ 60 years;
- Age < 60 years with spontaneous amenorrhea for ≥12 months; no chemotherapy, tamoxifen, toremifene or ovarian function suppression in the past 12 months, and post-menopausal levels of FSH and estradiol;
- Age < 60 years receiving tamoxifen or toremifene, with post-menopausal FSH and estradiol levels documented on two consecutive tests.
9、Adequate organ function (no blood product or growth-factor-supported correction within 14 days prior to first study drug administration):
- Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L.
- Hepatic and renal function: Albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen and serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
- Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO).
- Electrocardiogram: QTcF (Fridericia-corrected QT interval) ≤ 470 ms for female subjects.
10、For pre-menopausal women of child-bearing potential: serum pregnancy test negative within 7 days before initiation of study treatment; non-lactating. All enrolled female participants must use adequate barrier contraception throughout treatment and for 6 months after completion of study treatment.
11、Voluntarily agrees to participate, provides written informed consent, demonstrates good compliance and is willing to complete all study-related visits and procedures.
Exclusion Criteria:
- Breast cancer without histopathological confirmation.
- Bilateral breast cancer, inflammatory breast cancer or occult breast cancer.
- Prior anti-neoplastic therapy of any modality (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.). Definitive radiotherapy received within 4 weeks before first study drug dose, or palliative radiotherapy received within 2 weeks before first study drug dose.
- Concurrent receipt of any other anti-tumor therapy.
- History of other malignancies within the past 5 years, except for cured basal-cell skin carcinoma and carcinoma in situ of cervix.
- Participation in another investigational-drug clinical trial within 4 weeks prior to enrollment.
- Received immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone equivalent) within 2 weeks before first study drug administration; nasal or inhaled corticosteroids are permitted.
- Administration of live or attenuated vaccines within 4 weeks prior to first study drug dose.
- Major surgery unrelated to breast cancer within 4 weeks before first study drug dose, or incomplete recovery from such surgery.
- Active autoimmune disease, or history of autoimmune disease prone to relapse (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; hypothyroidism controlled solely by hormone-replacement therapy is allowed). Subjects with skin disorders not requiring systemic therapy (vitiligo, psoriasis, alopecia), insulin-controlled type 1 diabetes, or childhood-onset asthma fully resolved without adult-time intervention may be enrolled. Asthma requiring bronchodilator intervention is excluded.
- History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency, or history of organ transplantation.
- Uncontrolled or clinically significant cardiovascular-cerebrovascular disease. Any of the following occurring within 6 months prior to first dose: NYHA class III-IV congestive heart failure, myocardial infarction, cerebral infarction (lacunar infarction excluded), pulmonary embolism, unstable angina; arrhythmias requiring treatment at screening; primary cardiomyopathy (dilated, hypertrophic, arrhythmogenic right-ventricular, restrictive or unclassified cardiomyopathy); clinically significant history of QTc prolongation; second-degree type-II or third-degree atrioventricular block; female QTcF > 470 ms; atrial fibrillation (EHRA grade ≥ 2b); uncontrolled hypertension judged by investigator to make subject ineligible.
- Known or suspected interstitial pneumonia; moderate-to-severe pulmonary disease impairing respiratory function within 3 months before first dose that may confound detection/management of drug-related pulmonary toxicity, including idiopathic pulmonary fibrosis, organizing pneumonia / bronchiolitis obliterans, pulmonary embolism, severe asthma, severe COPD, obstructive/restrictive lung disease; autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (e.g. rheumatoid arthritis, Sjögren syndrome, sarcoidosis); prior total pneumonectomy.
- Active hepatitis B (HBsAg-positive with HBV-DNA ≥ 500 IU/mL), hepatitis C (HCV-antibody-positive with HCV-RNA above upper limit of normal), liver cirrhosis; severe infection requiring antibiotics, antiviral or antifungal therapy.
- Known inherited or acquired bleeding or thrombotic diathesis (e.g. hemophilia, coagulopathy).
- Known hypersensitivity or contraindications to study drugs or their excipients.
- Pregnant or lactating women; women of child-bearing potential with positive baseline serum pregnancy test; women of child-bearing potential unwilling to use effective contraception throughout the study period.
- Concomitant medical conditions that, in the investigator's judgment, would endanger subject safety or prevent completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection).
- Documented history of neurological or psychiatric disorders including epilepsy or dementia; or any other condition rendering the subject unsuitable for the study in the investigator's opinion.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Trastuzumab Rezetecan plus Toripalimab and Endocrine Therapy Neoadjuvant Treatment
|
Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pathological Complete Response Rate (pCR, ypT0/isN0)
時間枠:At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients achieving pathological complete response (pCR, defined as ypT0/isN0) in breast and axillary lymph nodes after neoadjuvant therapy, assessed by central pathology review after surgery |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients with confirmed objective response (CR or PR) assessed by investigator according to RECIST criteria. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Residual Cancer Burden (RCB)
時間枠:At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
RCB class and continuous RCB score determined from surgical specimens after neoadjuvant treatment. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Event-Free Survival (EFS)
時間枠:Up to 3 years after surgery
|
Time from enrollment to first occurrence of invasive breast cancer recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever comes first. |
Up to 3 years after surgery
|
|
Overall Survival (OS)
時間枠:Up to 5 years after surgery
|
Time from enrollment to death from any cause. |
Up to 5 years after surgery
|
|
Safety
時間枠:From start of study treatment up to 30 days after last dose of study drugs
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded per CTCAE. |
From start of study treatment up to 30 days after last dose of study drugs
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Immune biomarkers (sTIL, PD-L1, etc.)
時間枠:Baseline and at surgery
|
Assessment of immune biomarkers including stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression in baseline tumor samples and post-treatment surgical specimens. |
Baseline and at surgery
|
|
Ki-67 expression
時間枠:Baseline and at surgery
|
Change in Ki-67 proliferation index between baseline biopsy and surgical specimens after neoadjuvant therapy. |
Baseline and at surgery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- E20261415
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。